Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Former 'Bachelorette' welcomes 1st baby via emergency c-section - 25 Breakout Stars in Ongoing television Series
- 3Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
- 4Council removes proposal to rename park named after former president of Israel
- 5Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- Regeneron's experimental therapy combo effective in untreated cancer patients
- Alice Wong, founder of the Disability Visibility Project, dies at 51
- Palestinians protest against Israel's new death penalty law
- Young Muslims in Germany feel left out of Mideast debate, experts say
- Go With The Breeze: Grand Paragliding Spots On the planet
- Lebanon’s Hezbollah and Yemen’s Houthis join Iran in strike on Israel
- Tatiana Schlossberg's diagnosis puts spotlight on leukemia: What to know
- Whale stranded off Germany for days free again
- Ways to track down the Right Criminal Legal counselor
